Carpenter Technology Corporation (CRS)

NYQ – Цена в реальном времени. Валюта: USD

591.78

-7.46 (-1.24%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

566.01

-25.77 (-4.36%)

После закрытия: Jun 26, 2026, 7:54 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Carpenter Technology Corporation (CRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Carpenter Technology Corporation (CRS)

Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish

Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term

Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know

Carpenter (CRS) Upgraded to Buy: Here's Why

Carpenter Technology Gains on Record Earnings, Profits

Видео

No Data

Пресс-релизы

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Carpenter Technology Reports Third Quarter Fiscal Year 2026 Results

Carpenter Technology Declares Quarterly Cash Dividend

Carpenter Technology Announces CEO Transition Plan: Brian Malloy to Succeed Tony Thene as Chief Executive Officer on July 1, 2026; Tony Thene to Continue as Executive Chairman

Search stocks

Carpenter Technology Corporation (CRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Carpenter Technology Corporation (CRS)

Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish

Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term

Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know

Carpenter (CRS) Upgraded to Buy: Here's Why

Carpenter Technology Gains on Record Earnings, Profits

Видео

No Data

Пресс-релизы

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Carpenter Technology Reports Third Quarter Fiscal Year 2026 Results

Carpenter Technology Declares Quarterly Cash Dividend

Carpenter Technology Announces CEO Transition Plan: Brian Malloy to Succeed Tony Thene as Chief Executive Officer on July 1, 2026; Tony Thene to Continue as Executive Chairman